Incidence Rate for Hantavirus Infections without Pulmonary Syndrome, Panama by Armien, Blas et al.
Incidence Rate 
for Hantavirus 
Infections without 
Pulmonary 
Syndrome, 
Panama
Blas Armien, Juan M. Pascale, Carlos Munoz, 
Sang-Joon Lee, Kook L. Choi, Mario Avila, 
Candida Broce, Anibal G. Armien, 
Fernando Gracia, Brian Hjelle, 
and Frederick Koster
During 2001–2007, to determine incidence of all 
hantavirus infections, including those without pulmonary 
syndrome, in western Panama, we conducted 11 
communitywide surveys. Among 1,129 persons, antibody 
prevalence was 16.5%–60.4%. Repeat surveys of 476 found 
that patients who seroconverted outnumbered patients with 
hantavirus pulmonary syndrome by 14 to 1. 
I
n the Americas, hantavirus species that occur at low 
frequency are associated with the severe disease 
hantavirus pulmonary syndrome (HPS) (1,2), and species 
that occur at higher frequency are associated with milder 
disease (3–5). In Panama, HPS is caused by the Choclo 
virus, for which a common rodent, the fulvous pygmy 
rice rat (6), is host.  Serum antibody prevalence against 
this virus is 3%–33% in neighborhoods where HPS cases 
have occurred (7) and 16%–45% according to selected 
communitywide surveys (8). Neutralization-inhibition 
assays of antibody-positive serum indicated past infections 
caused by Choclo virus (9). To obtain a more accurate 
incidence of hantavirus infections in Panama, we conducted 
repeat surveys to identify hantavirus seroconversions 
during 1- to 3-year intervals between surveys. Our goal 
was to compare incidence of seroconversion with that of 
concurrent HPS in the same communities.
The Study
During 2001–2007, a total of 4 communities (3 in 
Los Santos Province and 1 in Veraguas Province) within 
hantavirus-endemic agroecosystems in western Panama 
were sampled 2–4 times at 1- to 3-year intervals (Table 
1). Informed written consent was obtained from all adult 
participants and from parents or legal guardians of minors. 
Consent and assent forms were reviewed and approved by 
institutional ethics review boards at the University of New 
Mexico, the Gorgas Memorial Institute in Panama City, and 
the protocol review committee of the International Centers 
for Infectious Diseases Research program of the National 
Institute of Allergy and Infectious Diseases. Eligible 
participants were all adults and children >2 years of age 
who permanently resided in each community according to 
the 2000 national census. The reasons for noninclusion in 
the ﬁ  rst and subsequent surveys were absence during the 
week of the survey and refusal to participate. 
A questionnaire administered to the head of household 
asked for a history of respiratory-related illnesses and 
hospitalizations within the past 3 years. Venous blood was 
collected from all family members for serologic testing. 
Results of the surveys were provided to each participating 
community through community meetings. Surveillance 
for HPS was conducted in the same communities as the 
serosurvey and nationally through reports to the Ministry of 
Health, and cases of HPS were conﬁ  rmed by questionnaire. 
The diagnosis of HPS required ﬁ  nding immunoglobulin 
(Ig) M in acute-phase serum, detection of Choclo virus 
RNA in serum by reverse transcription PCR, typical 
respiratory signs and symptoms, and chest radiographic 
ﬁ  ndings compatible with pulmonary edema.
Heparinized whole blood collected by arm 
venipuncture was separated by centrifugation; plasma 
was stored at −20°C until analysis. In binding assays, 
antibody to all known hantaviruses indigenous to the 
Americas cross-react with the N protein of Sin Nombre 
virus (10). A strip immunoblot assay for IgG containing 
recombinant N protein of the 3H226 genotype of Sin 
Nombre virus was used as described (10); the criterion 
for positivity was a dark band for Sin Nombre N protein 
at a serum dilution of 1:200. An enzyme immunoassay 
used recombinant nucleocapsid protein from Sin Nombre 
virus (11); the cutoff value was established at 3 SD 
above reactivity to a panel of known positive serum. All 
samples were tested by both assays; the concordance of 
the enzyme immunoassay and strip immunoblot assay in 
this study was 97%, and the criterion for seropositivity 
was a positive reaction in both assays. Loss of antibody 
in persons with previously positive serum was determined 
by 2 independent tests with both assays. IgM against 
hantavirus was not tested.  In Panama, all HPS patients 
tested have had positive reverse transcription PCR results 
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for Choclo genomic RNA in acute-phase blood samples 
(9), and antibody has been detected by both assays.
Data were transferred from ﬁ   eld collection forms 
to a database (Epi Info version 6.04d, Centers for 
Disease Control and Prevention, Atlanta, GA, USA) for 
statistical analyses using Epi Info software. Changes in 
seroprevalence within each community were tested by 
Fisher exact test for each interval and by longitudinal 
analysis for all intervals and communities by a generalized 
estimating equation (12). Increases in seroprevalence 
according to community and year of survey were tested 
by using analysis of covariance.
The 11 surveys repeatedly sampled 60%–85% of 
the total population of each community, for a total of 
1,838 samples from 1,129 persons. Overall antibody 
prevalence was 32.9%, varying from 16.5% to 60.4% 
in individual surveys (Table 1). In each of the 3 Los 
Santos communities (Agua Buena, Isla Cañas, San Jose), 
seroprevalence increased annually by ≈5% (Table 1); the 
overall seroprevalence increases for the combined Los 
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Table 1. Hantavirus seroprevalence, western Panama* 
Community and year of 
survey 
Community 
population
Persons tested, no. 
(% of community) 
No. (%) IgG 
positive† 
No. undergoing 
follow-up testing‡ 
Repeated tests only: 
no. (%) IgG positive†§ 
Agua Buena 
  2003  175 105 (60)  47 (44.8)  – –
  2004  175 108 (62)  59 (54.6)  75 41 (54.7) 
  2006  160 102 (64)  61 (60.4)  69 42 (61.8)¶ 
  2007  164 99 (60)  49 (49.5)  55 33 (60.0)# 
Isla Cañas 
  2001  276 223 (81)  74 (33.2)  – –
  2003  184 120 (65)  56 (46.7)  90 44 (48.9)** 
  2006  187 120 (64)  63 (52.5)  49 26 (53.1)# 
San Jose
  2001  593 486 (82)  80 (16.5)  – –
  2003  454 327 (72)  84 (25.7)  270 70 (25.7)# 
Borracherones 
  2003  85 61 (72)  19 (31.1)  – –
  2006  93 87 (94)  23 (26.4)  41 11 (26.8) 
*Ig, immunoglobulin; –, not applicable. 
†No. IgG positive (point prevalence % of seropositivity). 
‡No. persons tested in this and previous survey. 
§Increase for all 4 communities combined not significant. 
¶Increase in seroprevalence significant (p = 0.007) by Fisher exact test. 
#Increase for combining Los Santos localities and year, p = 0.0014. 
**Increase significant (p = 0.001). 
Table 2. Hantavirus seroconversions and HPS cases, western Panama* 
Community and survey 
intervals 
No. undergoing 
follow-up testing† 
No. seroconverted/
no. seronegative‡ 
No. conversions/ 
100 person-years 
No. seroreverted/ 
no. seropositive§  No. HPS cases¶ 
Agua Buena 
2003–2004 75 8/42 0/33 1
2004–2006 69 6/29 4/40 0
2006–2007 55 5/23 4/32 0
 Total  19 15.4 8 1
Isla Cañas
2001–2003 90 18/64  0/26 0
2003–2006 49 2/24 1/25 0
 Total  20 10.0 1 0
San Jose
2001–2003 270 29/228  1/42 3
 Total  29 6.4 1 3
Borracherones 
2003–2006 41 2/26 6/15 1
Total 2 2.6 6 1
Study totals  70 8.2 16 5
*HPS, hantavirus pulmonary syndrome. 
†No.persons repeat tested in this and previous survey. 
‡ No. seroconverted among subset who were seronegative at the beginning of the interval. 
§ No. seroreverted among subset who were seropositive at the beginning of the interval. 
¶HPS cases verified by Ministry of Health during interval in community. Santos communities were signiﬁ  cant (Fisher exact test, p 
= 0.0014). The changes in seroprevalence were community 
speciﬁ  c (analysis of covariance F = 5.24, p = 0.0043), but 
increases in seroprevalence in the 4 communities combined 
was not (general estimating equation).
Among the study population, seroconversion was 
documented for 70 persons, and HPS was diagnosed for 5 
other persons in the same communities during the intervals 
studied (Table 2). In the cohort of 476 persons in all 3 Los 
Santos communities sampled in 2 back-to-back surveys 
(Table 2), the 70 seroconversions occurred in persons in all 
age cohorts and equally among persons of both sexes (data 
not shown). No person who seroconverted gave a history of 
HPS-like illness or hospitalization for an acute respiratory 
illness. A separate study of outpatients with febrile 
illnesses was conducted in 4 clinics in the hantavirus-
endemic area. This study found 48 adults and children 
with the typical febrile prodrome, unremarkable chest 
radiographs, and either serum IgM speciﬁ  c for hantavirus 
nucleoprotein or Choclo virus genomic RNA in the acute-
phase blood sample (B. Armien and J.M. Pascale, unpub. 
data). These ﬁ  ndings of symptomatic hantavirus infections 
conﬁ  rm previous observations derived from neutralization-
inhibition antibody assays (9).
The incidence of 70 seroconversions in 857 person-
years of observation (Table 2) was equivalent to 8 
infections per 100 person-years. The ratio of infection 
detected by seroconversion to infection resulting in HPS 
was 14:1. The mean ages of persons who seroconverted 
(43 years) and those with HPS (43 years) were the same. 
Undercounting of HPS cases was not likely because HPS 
is a highly publicized illness throughout Panama, and 
diagnostic serologic testing is readily available through the 
Ministry of Health.
A  total of 16 seroreversions, compared with 70 
seroconversions, occurred among persons in most age 
cohorts, mean age 48 years. For HPS caused by Sin Nombre 
and Andes viruses, serum antibody typically persists for 
years (13). Serum antibodies after mild or asymptomatic 
infections may not persist for many years.
Conclusions
Antibody prevalence surveys are useful for 
identifying populations and locations at risk, monitoring 
changes in incidence, and focusing limited public health 
resources. Determining whether the observed increases 
in seroprevalence will be sustained requires additional 
surveys, but this information will be useful as the new 
agroeconomy increasingly emphasizes the monoculture of 
products (rice and sugar cane) favorable to rodents (14). 
Nonetheless, the documentation of large numbers of mild 
or asymptomatic hantavirus infections not progressing to 
HPS has identiﬁ  ed a larger effect of this zoonotic disease.
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